The role of patient preferences in Market Access

Learn how HTAs, HCPs and patients’ associations value patient preferences

No available dates

1 day event

Danish

0 DKK ex VAT
(app. 0 EUR ex VAT)
50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Approval bodies such as the FDA, EMA and NICE will soon focus on patient preference evidence when approving new medical treatments. It is therefore inevitable that pharma HQs will begin generating such evidence and expecting affiliates to utilize such evidence in Market Access and Commercial work.

At this course you gain an understanding of what Patient Preferences is, which methods to generate and measure patient preferences and how they can be used in a Danish context when working with Payers, HCPs and patient organizations.
 

Key words

  • Patient preferences
  • Patient Advocacy
  • Medical Affairs
  • Market Access
  • Stakeholder management
  • Health data
  • Evidence
  • Medicine evaluation
  • Danish Medicines Council

ANNIVERSARY OFFER:

Book any course* scheduled for a date in 2022 and bring a colleague along: 2 for the price of 1. Only valid for bookings made 2 May until 16 May.

Sign up yourself and a colleague in the same order form – then we make sure only one course fee is charged.

(*Networks and courses offered together with University of Copenhagen and CBS are not included.)

Read more

IS THIS COURSE FOR YOU?

This course is essential for you if you work with Medical Affairs, Market Access, Public Affairs, Sales, Marketing or Patient Advocacy.

Others interested in learning about patient preferences are also welcome.

What you will learn

  1. What patient preferences are and how they can be generated quantitatively and qualitatively
  2. How international approval bodies work with patient preferences, including the expectations of the Danish Medicines Council for the role played by the preferences in the Council's work in the future
  3. The relationship between HQ and subsidiaries regarding patient preferences
  4. How healthcare professionals and patients’ associations work with patient preferences in everyday life, and how pharmaceutical companies can contribute to that work

What your company will get

  1. An employee who understands patient preferences and how these can be utilised in cross-functional work during the product lifecycle from development and pre-approval to launch and post-launch
  2. An employee with knowledge about how patient preferences are included in approval bodies’ decision-making processes

Course information

Literature

Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course.

The mandatory readings are also part of the examination syllabus. 

Please download and read whitepaperet “The value of patient preference, DLIMI”. You can download it here.

Examination

There is no examination for this course.

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Birger Flinthagen at +45 39 15 09 06

Send me a message